Evidence map›Paper›PMID 39990097›Full record

ReviewResearch and practice in thrombosis and haemostasis2025

Recombinant factor VIIa: new insights into the mechanism of action through product innovation.

Miguel A Escobar, Maureane Hoffman, Giancarlo Castaman, Cedric Hermans, Johnny Mahlangu, Johannes Oldenburg, Charles L Percy, Mark T Reding, Amy D Shapiro, Steven W Pipe

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Miguel A EscobarGulf States Hemophilia and Thrombophilia Center, Houston, Texas, USA.
Maureane HoffmanDepartment of Veterans Affairs Medical Center, Pathology and Laboratory Medicine Service, Durham, North Carolina, USA.
Giancarlo CastamanDepartment of Oncology, Centre for Bleeding Disorders and Coagulation, Careggi University Hospital, Firenze, Italy.
Cedric HermansDivision of Hematology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium.
Johnny MahlanguDepartment of Molecular Medicine and Haematology, Hemophilia Comprehensive Care Center, University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa.
Johannes OldenburgDepartment of Experimental Hematology and Transfusion Medicine, Institute of Experimental Hematology and Transfusion Medicine, University Hospital Bonn, Medical Faculty, University of Bonn, Bonn, Germany.
Charles L PercyDepartment of Clinical Haematology, West Midlands Adult Comprehensive Care Haemophilia & Thrombosis Centre, Queen Elizabeth Hospital, Birmingham, UK.
Mark T RedingDepartment of Medicine, Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, Minnesota, USA.
Amy D ShapiroIndiana Hemophilia and Thrombosis Center, Indianapolis, Indiana, USA.
Steven W PipeDepartments of Pediatrics and Pathology, University of Michigan, Ann Arbor, Michigan, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Management of bleeding in persons with hemophilia and inhibitors involves treatment with bypassing agents, including recombinant activated factor VII (rFVIIa). Two rFVIIa products are commercially approved for use in the United States and the European Union. Eptacog alfa and eptacog beta share the same amino acid sequence but differ in posttranslational modifications. Although rFVIIa has been used to manage bleeding in persons with hemophilia and inhibitors for over 30 years, its mechanisms of action is still being studied.

Indexed as

blood plateletsendothelial protein C receptorfactor VIIahemophilia Ahemophilia Bhemostasistissue factor

Identifiers

PMID39990097
PMCPMC11847032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.